EMA accepts application for Polpharma Biologics’ MS biosimilar natalizumab 20-Jul-2022 By Rachel Arthur Polpharma Biologics’ Marketing Authorization Application for natalizumab – a proposed biosimilar to Biogen’s Tysabri – has been accepted by the European Medicines Agency (EMA).
Sandoz gains commercialization rights to Tysabri biosimilar 05-Sep-2019 By Vassia Barba Sandoz takes on the global commercialization of Polpharma’s late-stage natalizumab biosimilar candidate, indicated for the treatment of RRMS.